drugset
drugset / Trial / NCT04671069

Drug Interaction Study of MGL-3196 With Clopidogrel

NCT04671069 ↗

Phase 1 Completed 20 enrolled Madrigal Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the single and multiple-dose pharmacokinetics (PK) of MGL-3196 are affected by co-administration with clopidogrel in healthy subjects.

Timeline

Start
2019-07-26
Primary completion
2019-08-30
Completion
2019-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Resmetirom Small molecule 100 mg Oral
Background Clopidogrel Small molecule 75 mg —

Indications

No indication recorded.